La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Kwang Dong Pharmaceutical Résultats passés
Passé contrôle des critères 4/6
Kwang Dong Pharmaceutical has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 5.5% per year. Kwang Dong Pharmaceutical's return on equity is 7.1%, and it has net margins of 2.6%.
Informations clés
4.7%
Taux de croissance des bénéfices
4.3%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 11.3% |
| Taux de croissance des recettes | 5.5% |
| Rendement des fonds propres | 7.1% |
| Marge nette | 2.6% |
| Dernière mise à jour des bénéfices | 31 Mar 2024 |
Mises à jour récentes des performances passées
Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals
Mar 25
Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?
Dec 04
Recent updates
There Is A Reason Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Undemanding
Aug 06Kwang Dong Pharmaceutical's (KRX:009290) Solid Profits Have Weak Fundamentals
Mar 25Kwang Dong Pharmaceutical Co., Ltd.'s (KRX:009290) Price Is Right But Growth Is Lacking
Mar 20Is Kwang Dong Pharmaceutical (KRX:009290) Using Too Much Debt?
Apr 29Is Now The Time To Put Kwang Dong Pharmaceutical (KRX:009290) On Your Watchlist?
Apr 06Did Business Growth Power Kwang Dong Pharmaceutical's (KRX:009290) Share Price Gain of 117%?
Mar 18Is Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Popular Amongst Insiders?
Mar 01Should Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Be Part Of Your Dividend Portfolio?
Feb 14Estimating The Fair Value Of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
Feb 01Kwang Dong Pharmaceutical (KRX:009290) Seems To Use Debt Quite Sensibly
Jan 19If You Like EPS Growth Then Check Out Kwang Dong Pharmaceutical (KRX:009290) Before It's Too Late
Jan 06Here's What We Like About Kwang Dong Pharmaceutical's (KRX:009290) Upcoming Dividend
Dec 24Can You Imagine How Kwang Dong Pharmaceutical's (KRX:009290) Shareholders Feel About The 54% Share Price Increase?
Dec 18Is There More To The Story Than Kwang Dong Pharmaceutical's (KRX:009290) Earnings Growth?
Dec 04What Type Of Shareholders Own The Most Number of Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290) Shares?
Nov 21Ventilation des recettes et des dépenses
Comment Kwang Dong Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 1,569,991 | 41,121 | 240,262 | 13,816 |
| 31 Dec 23 | 1,514,454 | 36,966 | 233,848 | 15,275 |
| 30 Sep 23 | 1,509,981 | 38,578 | 232,566 | 11,458 |
| 30 Jun 23 | 1,489,793 | 36,189 | 232,638 | 11,757 |
| 31 Mar 23 | 1,476,248 | 30,631 | 228,270 | 11,346 |
| 31 Dec 22 | 1,431,545 | 24,174 | 225,646 | 9,678 |
| 30 Sep 22 | 1,412,478 | 23,615 | 222,668 | 9,416 |
| 30 Jun 22 | 1,385,264 | 26,115 | 214,282 | 9,013 |
| 31 Mar 22 | 1,356,287 | 25,453 | 212,986 | 8,383 |
| 31 Dec 21 | 1,338,182 | 24,019 | 212,961 | 8,322 |
| 30 Sep 21 | 1,282,056 | 10,642 | 205,552 | 6,955 |
| 30 Jun 21 | 1,247,496 | 32,216 | 201,993 | 6,401 |
| 31 Mar 21 | 1,237,240 | 40,840 | 197,840 | 6,855 |
| 31 Dec 20 | 1,243,770 | 45,370 | 195,678 | 5,957 |
| 30 Sep 20 | 1,256,388 | 54,621 | 200,963 | 5,704 |
| 30 Jun 20 | 1,244,064 | 28,203 | 203,172 | 5,830 |
| 31 Mar 20 | 1,244,963 | 24,627 | 201,986 | 5,164 |
| 31 Dec 19 | 1,238,255 | 23,058 | 199,916 | 5,339 |
| 30 Sep 19 | 1,215,667 | 22,304 | 193,417 | 5,967 |
| 30 Jun 19 | 1,224,386 | 26,756 | 189,914 | 5,186 |
| 31 Mar 19 | 1,198,939 | 24,200 | 192,269 | 4,919 |
| 31 Dec 18 | 1,180,220 | 22,345 | 192,967 | 4,179 |
| 30 Sep 18 | 1,163,673 | 23,471 | 192,490 | 3,200 |
| 30 Jun 18 | 1,148,402 | 25,169 | 194,426 | 3,221 |
| 31 Mar 18 | 1,152,533 | 24,153 | 199,724 | 2,307 |
| 31 Dec 17 | 1,141,566 | 23,196 | 200,515 | 1,513 |
| 30 Sep 17 | 1,128,693 | 22,482 | 203,338 | 858 |
| 30 Jun 17 | 1,100,137 | 20,602 | 204,298 | 0 |
| 31 Mar 17 | 1,076,306 | 26,392 | 199,417 | 0 |
| 31 Dec 16 | 1,056,429 | 28,063 | 194,647 | 0 |
| 30 Sep 16 | 1,066,944 | 31,922 | 190,380 | 0 |
| 30 Jun 16 | 1,076,681 | 33,587 | 187,110 | 0 |
| 31 Mar 16 | 1,077,617 | 35,062 | 180,196 | 0 |
| 31 Dec 15 | 955,454 | 35,015 | 174,183 | 0 |
| 30 Sep 15 | 808,363 | 36,695 | 163,777 | 0 |
| 30 Jun 15 | 674,913 | 37,955 | 151,727 | 0 |
| 31 Mar 15 | 533,999 | 36,215 | 142,453 | 0 |
| 31 Dec 14 | 522,274 | 35,044 | 137,462 | 0 |
| 30 Sep 14 | 508,923 | 32,721 | 133,358 | 0 |
| 30 Jun 14 | 497,111 | 31,688 | 130,118 | 0 |
| 31 Mar 14 | 479,965 | 23,047 | 123,906 | 0 |
| 31 Dec 13 | 468,385 | 22,037 | 120,328 | 0 |
| 30 Sep 13 | 436,423 | 23,110 | 112,355 | 0 |
Des revenus de qualité: A009290 has a large one-off gain of ₩20.0B impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: A009290's current net profit margins (2.6%) are higher than last year (2.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: A009290's earnings have grown by 4.7% per year over the past 5 years.
Accélération de la croissance: A009290's earnings growth over the past year (34.2%) exceeds its 5-year average (4.7% per year).
Bénéfices par rapport au secteur d'activité: A009290 earnings growth over the past year (34.2%) exceeded the Pharmaceuticals industry 23.5%.
Rendement des fonds propres
ROE élevé: A009290's Return on Equity (7.1%) is considered low.